Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

A compound having the general formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is hetAr1(CH2)m—, hetAr2CH2— or hetAr3CH2;
• hetAr1 is a 6-membered heteroaryl having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, (1-4C)alkoxy, halogen, CF3, or (3-6C)cycloalkyl;
• m is 0, 1 or 2;
• hetAr2 is a 5-membered heteroaryl ring having 2-3 ring heteroatoms independently selected from N and S where at least one of said heteroatoms is N, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl;
• hetAr3 is a bicyclic 5,6-fused heteroaryl ring having two ring nitrogen atoms;
• R2 is CH3;
• R3 is H;
• R4 is H;
• R5 is hetCyc4(1-4C)alkoxy or hetCyc5(1-4C)alkoxy;
• hetCyc4 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N, O and S, wherein one of said ring nitrogen atoms is optionally oxidized to N(O) and wherein said S ring atom is optionally oxidized to SO or SO2, wherein hetCyc4 is optionally substituted with one or more substituents independently selected from halogen, OH, (1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, (1-4C)alkyl-OC(═O)— and (1-6C)alkoxy;
• hetCyc5 is a spiro heterocycle having 2 ring heteroatoms independently selected from N and O, wherein hetCyc5 is optionally substituted with a group selected from (1-6C)alkyl;
• and
• R6 is H.